Literature DB >> 508552

Kinetics of placentally transferred phenytoin and its p-hydroxylated metabolites in newborn infants.

A Rane, C Hoppel, B Höjer.   

Abstract

1 The kinetics of phenytoin and its main metabolites, unconjugated and conjugated 4-hydroxy-phenytoin were studied in newborn infants of epileptic mothers that were treated with phenytoin during the pregnancy. 2 In two of the infants phenytoin was eliminated by an apparent zero-order process followed by an apparent first-order process. In the other two infants the mode of elimination could not be characterized. 3 The decline of plasma conjugated 4-hydroxy-phenytoin was parallel to that of phenytoin. In contrast, the plasma concentration of unconjugated 4-hydroxy-phenytoin remained grossly constant during the first 3 to 4 days.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 508552      PMCID: PMC1429825          DOI: 10.1111/j.1365-2125.1979.tb01027.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  10 in total

1.  Body water compartments in children: changes during growth and related changes in body composition.

Authors:  B FRIIS-HANSEN
Journal:  Pediatrics       Date:  1961-08       Impact factor: 7.124

2.  Urinary corticosteriod and diphenylhydantoin metabolite patterns in neonates exposed to anticonvulsant drugs in utero.

Authors:  J W Reynolds; B L Mirkin
Journal:  Clin Pharmacol Ther       Date:  1973 Sep-Oct       Impact factor: 6.875

3.  Urinary excretion of diphenylhydantoin metabolites in newborn infants.

Authors:  A Rane
Journal:  J Pediatr       Date:  1974-10       Impact factor: 4.406

4.  Plasma disappearance of transplacentally transferred diphenylhydantoin in the newborn studied by mass fragmentography.

Authors:  A Rane; M Garle; O Borgå; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1974-01       Impact factor: 6.875

5.  Inhibition of diphenylhydantoin elimination by its major metabolite.

Authors:  J J Ashley; G Levy
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1972-09

6.  Metabolic disposition of diphenylhydantoin in normal human subjects following intravenous administration.

Authors:  A J Glazko; T Chang; J Baukema; W A Dill; J R Goulet; R A Buchanan
Journal:  Clin Pharmacol Ther       Date:  1969 Jul-Aug       Impact factor: 6.875

7.  Mass fragmentographic determination of diphenylhydantoin and its main metabolite, 5-(4-hydroxyphenyl)-5-phenylhydantoin, in human plasma.

Authors:  C Hoppel; M Garle; M Elander
Journal:  J Chromatogr       Date:  1976-01-07

8.  The metabolism of 5,5-diphenylhydantoin (DPH) in nonpregnant and pregnant Rhesus monkeys.

Authors:  W L Gabler; G L Hubbard
Journal:  Arch Int Pharmacodyn Ther       Date:  1973-05

9.  [The significance of cumulation and elimination for the determination of Phenytoin (diphenylhydantoin)].

Authors:  H Remmer; J Hirschmann; I Greiner
Journal:  Dtsch Med Wochenschr       Date:  1969-06-13       Impact factor: 0.628

10.  The rate of decline of diphenylhydantoin in human plasma.

Authors:  K Arnold; N Gerber
Journal:  Clin Pharmacol Ther       Date:  1970 Jan-Feb       Impact factor: 6.903

  10 in total
  2 in total

Review 1.  Anticonvulsants during pregnancy and lactation. Transplacental, maternal and neonatal pharmacokinetics.

Authors:  H Nau; W Kuhnz; H J Egger; D Rating; H Helge
Journal:  Clin Pharmacokinet       Date:  1982 Nov-Dec       Impact factor: 6.447

Review 2.  The pharmacokinetics of antiarrhythmic agents in pregnancy and lactation.

Authors:  G M Mitani; I Steinberg; E J Lien; E C Harrison; U Elkayam
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.